Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farm...
XP Chemistries godkännande gällande användning av bolagets kapsaicin som fodertillsats för alla djur...
* CFO and new CEO gave a general presentation * Some positive market signs, mainly in public and tel...
Tove Christiansson, currently Head of the Assistive Tech Business Area at MedCap, will take on the r...
Redeye comments on decision by the VGR Regional Board regarding Millennium and the modular alternati...
Redeye gives a short comment on the news that a bill has been passed in the US House of Representati...
Redeye provides a summary of Sdiptech’s CMD. The event presented slightly updated financial targets,...
The change from a 510k back to its original De Novo pathway is mostly a non-event for the case.
SyntheticMR redovisade ett svagt tredje kvartal där omsättningen sjönk med 7 procent och resultatet ...
Following Fiskars' profit warning on 19 November, we cut 2025E adjusted EBIT by 9%, while we make mo...
Redeye retains its positive take on Formpipe following the finalisation of the Public divestment and...
Today, Monday, 1 December, is the ex-rights date for the preferential rights issue, marking the firs...
Redeye provides an update following Mindark’s Q3 2025 report.
Redeye provides an update following CI Games’ Q3 report, which demonstrated slightly softer-than-ant...
Mindark redovisade ökad nettoomsättning och minskad EBIT i det tredje kvartalet.
mResell levererade ett rekordstarkt tredje kvartal med 167,3 % tillväxt, där totala intäkter steg ti...
Redeye comments on MindArk’s Q3 results, which showed figures in line with estimates, apart from sli...
Redeye comments on the USTR’s confirmation that the Section 301 tariff exemption for computer cases ...
Redeye provides a summary of Paxman’s CMD. The event offered no material surprises and introduced li...
Redeye comments on FluoGuide’s Q3 2025 report. The company has posted a busy news flow in recent mon...
